Balchem Corporation Reports Record Q1 2026 Earnings with Continued Adjusted EBITDA Growth
Balchem Corporation achieved record first-quarter results in Q1 2026, driven by its 27th consecutive quarter of year-over-year adjusted EBITDA growth. The company's Human Nutrition & Health segment benefited from consumer trends toward nutrient-dense products, while Animal Nutrition & Health saw increased market penetration and recovery in Europe. Specialty Products also performed well due to improved market conditions.
Topics: adjusted_ebitda earnings gross_margin growth outlook segment_performance strategic_investment